Reported Earnings • May 28
Full year 2026 earnings released: EPS: ₹0.034 (vs ₹1.21 in FY 2025) Full year 2026 results: EPS: ₹0.034 (down from ₹1.21 in FY 2025). Revenue: ₹3.69b (up 14% from FY 2025). Net income: ₹635.0k (down 97% from FY 2025). Profit margin: 0% (down from 0.7% in FY 2025). The decrease in margin was driven by higher expenses. Tillkännagivande • May 22
Cell Point (India) Limited to Report Second Half, 2026 Results on May 27, 2026 Cell Point (India) Limited announced that they will report second half, 2026 results on May 27, 2026 Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹15.60, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 19x in the Specialty Retail industry in India. Total loss to shareholders of 13% over the past year. New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Earnings have declined by 7.6% per year over the past 5 years. Market cap is less than US$10m (₹254.1m market cap, or US$2.72m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Large one-off items impacting financial results. Reported Earnings • Nov 18
First half 2026 earnings released: EPS: ₹0.10 (vs ₹0.12 in 1H 2025) First half 2026 results: EPS: ₹0.10 (down from ₹0.12 in 1H 2025). Revenue: ₹1.77b (up 15% from 1H 2025). Net income: ₹1.91m (down 15% from 1H 2025). Profit margin: 0.1% (in line with 1H 2025). New Risk • Nov 13
New major risk - Revenue and earnings growth Earnings have declined by 7.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.0x net interest cover). Earnings have declined by 7.6% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹344.7m market cap, or US$3.89m). Tillkännagivande • Nov 07
Cell Point (India) Limited to Report First Half, 2026 Results on Nov 12, 2025 Cell Point (India) Limited announced that they will report first half, 2026 results on Nov 12, 2025 Tillkännagivande • Sep 03
Cell Point (India) Limited, Annual General Meeting, Sep 27, 2025 Cell Point (India) Limited, Annual General Meeting, Sep 27, 2025, at 11:30 Indian Standard Time. Location: 30-12-139, first floor, room no.5&6, ramas arcade, dabagardens, visakhapatnam, ap - 530020, India New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Market cap is less than US$10m (₹331.7m market cap, or US$3.79m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results. New Risk • Jun 25
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 502% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Market cap is less than US$10m (₹347.6m market cap, or US$4.05m). Minor Risk Large one-off items impacting financial results. New Risk • May 21
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Market cap is less than US$10m (₹330.7m market cap, or US$3.86m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (0.07% net profit margin). Tillkännagivande • Sep 27
Cell Point (India) Limited Declares Final Dividend for the Financial Year Ended March 31, 2024 Cell Point (India) Limited announced at the AGM held on September 27, 2024, approved declare final dividend on equity shares at the rate of 2.5% [i.e. INR 0.25/- (Rupees Twenty Five paisa only) per Equity Share of Face Value of INR 10/- (Rupees Twenty Five paisa only) for the financial year ended March 31, 2024. Tillkännagivande • Sep 13
Cell Point (India) Limited, Annual General Meeting, Sep 27, 2024 Cell Point (India) Limited, Annual General Meeting, Sep 27, 2024, at 11:30 Indian Standard Time. Location: 30-12-139, first floor, room no.5&6, ramas arcade, dabagardens, visakhapatnam, ap-530009, India New Risk • May 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (35% accrual ratio). Market cap is less than US$10m (₹644.7m market cap, or US$7.74m). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹37.30, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 48x in the Specialty Retail industry in India. New Risk • Nov 22
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹820.3m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (35% accrual ratio). Market cap is less than US$10m (₹820.3m market cap, or US$9.85m). New Risk • Nov 20
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 35% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (35% accrual ratio). Minor Risk Market cap is less than US$100m (₹833.4m market cap, or US$10.0m). Tillkännagivande • Sep 08
Cell Point (India) Limited, Annual General Meeting, Sep 29, 2023 Cell Point (India) Limited, Annual General Meeting, Sep 29, 2023, at 11:30 Indian Standard Time. Location: Door No 30-15-139/F/5, 6 Ward No 27, Ram's Arcade Opposite Visakha Medical Centre, Dabagardens Visakapatnam Andhra Pradesh India Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹55.55, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 38x in the Specialty Retail industry in India. Reported Earnings • Jul 22
Full year 2023 earnings released: EPS: ₹4.93 (vs ₹1.21 in FY 2022) Full year 2023 results: EPS: ₹4.93 (up from ₹1.21 in FY 2022). Revenue: ₹2.96b (up 9.8% from FY 2022). Net income: ₹67.3m (up 309% from FY 2022). Profit margin: 2.3% (up from 0.6% in FY 2022). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment deteriorates as stock falls 32% After last week's 32% share price decline to ₹49.05, the stock trades at a trailing P/E ratio of 55.7x. Average trailing P/E is 38x in the Specialty Retail industry in India. Board Change • Jun 29
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Ananda Ravada was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
